Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma - LARVOL DELTA

A Case of Graft-Versus-Host Disease in a Liver Transplant Recipient Receiving an HCV NAT Positive Organ: Does HCV NAT Matter? (PubMed, Transplant Proc) - "Treating GVHD with ruxolitinib and HCV with glecaprevir/pibrentasvir simultaneously is both effective and safe."

Journal • Bone Marrow Transplantation • Graft versus Host Disease • Hepatology • Immunology • Solid Organ Transplantation • Transplantation

Glecaprevir/Pibrentasvir Concentrations in the Breastmilk of Lactating Women. (PubMed, Clin Infect Dis) - "In this prospective pharmacokinetic study of women undergoing chronic hepatitis C virus treatment with glecaprevir/pibrentasvir, the mean glecaprevir and pibrentasvir concentrations in breastmilk were 0.63% and 4.23% of maternal plasma concentrations, with a mean relative infant dose of 0.02% and 0.06%, respectively."

Journal • Hepatitis C • Infectious Disease • Inflammation

Expanding the Intestinal Donor Pool: Use of Hepatitis CâPositive Donors in Small Bowel Transplantation (ACG 2026) - "DAA therapy (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) was initiated between postoperative days 3â10. These findings support the selective use of HCV-positive donors to expand the intestinal graft pool. Larger multicenter cohorts with extended follow-up are needed to validate long-term safety and optimize antiviral protocols."

Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplant Rejection • Transplantation

Trends in Medicare Part D and Medicaid Utilization and Spending on Hepatitis C Direct-Acting Antiviral Agents: 2019â2024 (ACG 2026) - "Glecaprevir/pibrentasvir declined 75.0% ($660M to $165M) and glecaprevir/pibrentasvir was the dominant agent, with spending declining from $1.19B to $692.9M (-41.9%) and claims falling 33.0% (80,940 to 54,252). Substantial declines in utilization and inflation-adjusted spending were observed across both programs. In Medicare Part D, sofosbuvir/velpatasvir remained the most utilized DAA in 2024 (31,431 claims; -24.4%), with spending falling 39.1% ($1.24B to $758M). Ledipasvir/sofosbuvir and elbasvir/grazoprevir experienced near-complete market exit, with spending reductions of 96.1% and 97.3%, respectively."

Medicaid • Medicare • Reimbursement • US reimbursement • Hepatitis C • Hepatology • Infectious Disease • Inflammation

IMPAACT 2041: Designing the Study of Glecaprevir/Pibrentasvir Treatment During Pregnancy. (PubMed, Open Forum Infect Dis) - "International Maternal Pediatric Adolescent AIDS Clinical Trials 2041 is a multicenter single-arm phase I/II clinical trial designed to evaluate the pharmacokinetics and safety of GLE/PIB treatment initiated in pregnant women with HCV mono-infection or HCV/HIV co-infection. In this paper, we describe the relevant background data assembled from various sources to write the protocol and design the study."

Journal • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Pediatrics

Successful administration of glecaprevir/pibrentasvir via percutaneous endoscopic gastrostomy in a pediatric patient with chronic hepatitis C and spinal muscular atrophy receiving risdiplam. (PubMed, Clin J Gastroenterol) - "We report a case of a 14-year-old dysphagic patient with SMA, receiving Risdiplam, who was successfully treated with crushed GLE/PIB administrated via PEG. The patient achieved a sustained virologic response (SVR) 12 weeks after the end of therapy, without significant adverse effects, and no drug interactions were observed during the course of treatment."

Journal • Gastrointestinal Disorder • Genetic Disorders • Hepatitis C • Infectious Disease • Inflammation • Movement Disorders • Muscular Atrophy • Pediatrics • Rare Diseases

Re-Engagement of Hepatitis C Patients Lost to Follow-Up: A Multicenter Study from Argentina (PubMed, Acta Gastroenterol Latinoam) - "Antiviral therapy began in 224 patients: sofosbuvir/velpatasvir 70.1% and glecaprevir/pibrentasvir 29.9%. Complementary case-finding plus a two-visit pathway enabled effective re-engagement and timely treatment, achieving near-universal SVR. This scalable model supports HCV micro-elimination across public hospital networks."

Clinical • Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Transplantation

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Oct 2027 ➔ Mar 2028 | Trial primary completion date: Oct 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Short Perioperative Antiviral Prophylaxis for Hepatitis C Viremic Donor Kidney Transplantation: Outcomes in 204 Recipients. (PubMed, Transplantation) - "Seven-day perioperative sofosbuvir/velpatasvir prophylaxis achieved SVR after prophylaxis alone in >92% of D+/R- kidney transplant recipients, with favorable 1-y clinical outcomes. Given the nonstructural protein 5A resistance-associated substitutions observed, we have transitioned to 7-d glecaprevir/pibrentasvir prophylaxis; outcomes will be reported via the REFORM-HEPC registry. These findings provide real-world evidence supporting the feasibility of short-course antiviral prophylaxis in HCV-viremic donor kidney transplantation."

Journal • Hepatitis C • Infectious Disease • Inflammation • Transplantation

Treatment of Hepatitis C During Pregnancy: We Are Approaching a "Tipping Point". (PubMed, Clin Infect Dis) - No abstract available

Journal • Hepatitis C • Infectious Disease • Inflammation

Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy. (PubMed, Clin Infect Dis) - "We report our experience with prenatal GLE/PIB in 14 patients. Ten patients completed treatment; all achieved virologic response by or at delivery, with no maternal or neonatal safety concerns."

Journal • Real-world evidence • Hepatitis C • Infectious Disease • Inflammation

STRIVE-4: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: Kirby Institute | Trial completion date: Feb 2026 ➔ Jul 2029 | Trial primary completion date: Feb 2026 ➔ Jul 2029

Trial completion date • Trial primary completion date • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Real-world effectiveness of sofosbuvir/velpatasvir retreatment in people living with HIV and recurrent hepatitis C (AIDS 2026) - "Although international guidelines recommend sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) or glecaprevir/pibrentasvir for retreatment, these regimens are unavailable in Colombia. SOF/VEL retreatment in DAA-experienced PLWH achieved clinically meaningful SVR12, although lower than rates reported for guideline-recommended salvage regimens. Outcomes were primarily influenced by behavioral and host factors rather than virological resistance. Advancing HCV micro-elimination in PLWH with recurrent infection in resource-limited settings will require integrated strategies combining optimal HIV suppression, adherence support, sexual-health interventions, and harm-reduction programs."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long-Standing Chronic Hepatitis C Virus Infection. (PubMed, J Med Virol) - "Seven individuals received glecaprevir/pibrentasvir (GLE/PIB) and one individual received sequential sofosbuvir/velpatasvir/ribavirin followed by GLE/PIB. Cases in this study also show that HCV-infected chimpanzees, like humans, are susceptible to HCC in the late stages of chronic infection. We recommend lifelong HCC surveillance for all HCV-exposed chimpanzees."

Journal • Fibrosis • Hepatitis C • Hepatocellular Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor

Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. (PubMed, J Viral Hepat) - "Sofosbuvir/ledipasvir and glecaprevir/pibrentasvir were the two most common regimens. Despite the large economic impact, the rapid uptake of DAA therapy suggests an active program of case finding and treatment with the goal of HCV elimination in Japan. Whereas the demographics of people receiving DAA therapy changed over time, treatments were provided uniformly across the nation."

HEOR • Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

CONGENITAL HEMOPHILIA A WITH HIGH-TITER INHIBITOR AND ESSENTIAL THROMBOCYTHEMIA: A RARE COEXISTENCE (ISTH 2026) - "He also had chronic hepatitis C, treated with glecaprevir/pibrentasvir...However, the identification of a femoral pseudotumor triggered emicizumab initiation, along with hydroxyurea (HU) to mitigate ET-related thrombotic risk...Conclusions This case highlights the therapeutic challenge in patients with both bleeding and thrombotic disorders, emphasizing the need for more clinical experience to determine optimal management. DOI*10.1016/j.rpth.2026.104361"

Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Hemophilia • Hemophilia A • Hepatitis C • Hepatology • Infectious Disease • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Rare Diseases • Thrombocytosis • Thrombosis • JAK2

ELIMINATION OF HCV IN CHILDREN AND YOUNG PEOPLE THROUGH A COLLABORATIVE VIRTUAL NETWORK (ESPGHAN 2026) - "Genotypes 1&3 were commonest; Sofosbuvir/Ledipasvir (Harvoni) prescribed in 76; Sofosbuvir/Velpatasvir (Epclusa) in 65; & Glecaprevir/Pibrentasvir (Maviret) in 16 with >99% clearance at EoT; 1 required re-treatment due to resistance. Treatment success was >99% in those who completed treatment with 100% confirmed SVR 12m. It has enhanced access to anti-viral therapy for CYP preventing long-term liver disease and transmission of HCV making a fundamental contribution to achieving the NHSE target to eliminate HCV in CYP ahead of the WHO 2030 target."

Clinical • Hepatitis C • Hepatology

Glecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection. (PubMed, Infect Dis Ther) - P3 | "Individuals with acute HCV infection with a history of prior HCV infection can be successfully treated with G/P. Risk of reinfection in high-risk populations, such as high-risk sexual activity or injection drug use, highlights the need for ongoing testing for reinfection along with subsequent treatment."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

AbbVie…announced that the European Commission approved MAVIRET (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older (PRNewswire) - "With this approval, MAVIRET is now the only treatment approved in the European Union for both acute and chronic HCV infection....The approval was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVIRET eight-week treatment regimen in patients with acute HCV infection."

EMA approval • Hepatitis C • Infectious Disease

Outcomes of Breakthrough Infections, Antiviral Resistance, and Cure Rates After Short Direct-Acting Antiviral (DAA) Prophylaxis in HCV-Viremic Kidney Donors to HCV-Negative Recipients (D+/R-) (ATC 2026) - "All subjects received an initial dose of sofosbuvir/velpatasvir (SOF/VEL) on day 0 ≤6 hours prior to transplant and then daily for a total of 7 days...Initial therapy consisted of glecaprevir/pibrentasvir (G/P) in 13 of 15 cases and SOF/VEL in 2 cases; one patient who failed G/P subsequently achieved SVR using SOF/VEL/voxilaprevir plus ribavirin for 12 weeks... Breakthrough HCV infection occurred in a small proportion (7.4%) of recipients receiving 7-day DAA prophylaxis after HCV D+/R- kidney transplantation. Although NS5A resistance-associated substitutions were identified in a subset of cases, the vast majority (93%) achieved sustained virologic response with a standard 12-week treatment course, and the single initial non-responder was cured with salvage therapy. These findings demonstrate that short prophylaxis yields low transmission rates, and that breakthrough infections—when they occur—remain consistently curable with appropriately selected DAA regimens."

Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (clinicaltrials.gov) - P=N/A | N=21 | Terminated | Sponsor: Kirby Institute | Once recruitment recommenced it remained slow. Removal of Sofosbuvir from the PBS November 2020 impacted recruitment into Cohort B. Study closed early on 15-Sep-26.

Enrollment change • Trial completion date • Trial termination • Fibrosis • Hepatitis C • Infectious Disease • Inflammation • Liver Cirrhosis • CD4

CROI 2026: Advances in Epidemiology and Treatment of Viral Hepatitis. (PubMed, Top Antivir Med) - "Data were presented from a phase III trial examining the safety and efficacy of bulevirtide, an investigational agent for hepatitis D treatment. Pharmacokinetic data in animal models from a long-acting injectable intraparticle coformulation of glecaprevir/pibrentasvir were presented for the treatment of hepatitis C. Several abstracts highlighted interventions to increase hepatitis C virus infection detection rates, such as rapid or point-of-care testing, and others focused on improving linkage to care to increase hepatitis C treatment and sustained virologic response rates. Finally, a single abstract showed 2 investigational agents with antiviral activity for hepatitis E virus infection."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Association of CBC-Derived Indices of Inflammation with Response to Glecaprevir/Pibrentasvir for PTSD. (PubMed, Psychopharmacol Bull) - "Regression coefficients for the statistically significant findings ranged from -19.56 (95% CI: -28.99, -10.14) to -14.24 (95% CI: -25.51, -2.98), indicating lower post-treatment CAPS scores in patients with greater inflammatory indices. CBC-derived indices of inflammation may be an efficient and widely available biomarker for predicting treatment response in medications targeting potential inflammatory mechanisms of PTSD."

Journal • CNS Disorders • Inflammation • Mood Disorders • Post-traumatic Stress Disorder

In Vivo Evidence of Human Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 Mediated Disposition of Glycyrrhizin and Its Drug-Drug Interactions in Humanized Mice. (PubMed, Phytother Res) - "Furthermore, we evaluated drug-drug interactions between glycyrrhizin and glecaprevir/pibrentasvir, a clinically relevant combination...Our study provides the first in vivo evidence of glycyrrhizin hepatic transport by human OATP1B1 and OATP1B3, emphasizing the need for careful dosing in patients with variable OATP1B/1B3 activity due to transporter-mediated drug-drug interactions. Additionally, this humanized mouse model can serve as a robust in vivo tool for the prediction of human OATP1B1 and 1B3 function."

Journal • Preclinical • Nephrology • Renal Disease

Feasibility and Acceptability of HCV Treatment in Pregnancy (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Feb 2026 ➔ Dec 2026 | Trial primary completion date: Feb 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hepatitis C • Infectious Disease • Inflammation